Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma

Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma

Metastatic disease from uveal melanoma occurs in almost 50% of patients suffering from this ocular tumour, with median survival from development of symptoms being around 1 year. In contrast to cutaneous melanoma, kinase inhibitors and immune checkpoint inhibitors are usually ineffective in patients...

Full description

Bibliographic Details
Main Authors: Bertil E. Damato, Joseph Dukes, Howard Goodall, Richard D. Carvajal
Format: Article
Language:English
Published: MDPI AG 2019-07-01
Series:Cancers
Subjects:
metastatic uveal melanoma
immunotherapy
tebentafusp
T cell
clinical data
preclinical data
ImmTAC platform
T cell receptor
anti-CD3 bispecific
Online Access:https://www.mdpi.com/2072-6694/11/7/971

Similar Items

Similar Items